|
James is responsible for supporting the pharmacokinetic (PK) and toxicokinetic (TK) aspects of drug discovery, development, and life cycle management. His expertise is in the design, implementation, and analysis of animal and human trials for the identification of the time courses of critical indicators of a drug’s presence, performance, and toxicity, integrating PK/TK parameters with pharmacodynamic findings. Jim is founder and president of Longstreth & Associates, Inc. He has also held a number of scientific positions at Searle/Monsanto.
Jim received his Ph.D. in biomedical engineering from The Johns Hopkins University. | 